Skip to content
Sign in
Artwork for NeuroFrontiers
ScienceLife Sciences

NeuroFrontiers

Practical Neurology

Practical Neurology partners with ReachMD to bring you clinical research and advancements that further clinicians' ability to diagnose and treat neurologic conditions. 

Play
Open in
  • 16 episodes
  • Avg 13 min
  • English

Episodes 16

NewestOldestLongest
All16Unplayed16In progress0Played0
  • September 4 · 8 min

    Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial

    Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease. Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health

  • July 17 · 15 min

    Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease

    In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trials as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.

  • June 23 · 10 min

    Advancing MOGAD Care

    Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.

  • May 15 · 16 min

    Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances

    Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information provided by Amgen, last updated 12/2025.

  • Oct 29, 2025 · 8 min

    The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis

    Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.

  • May 7, 2025 · 21 min

    New Guidelines for the Assessment of Traumatic Brain Injury

    Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.

  • Mar 22, 2025 · 14 min

    The Impact of High Efficacy DMTs on Paramagnetic Rim Lesions

    Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progression of multiple sclerosis.

  • Mar 14, 2025 · 15 min

    Proposed Hospital Standards for Parkinson Disease Care Aim to Avoid Preventable Harm

    Preventable harm is a serious concern for patients with Parkinson disease who receive care in the hospital setting, even when admitted for reasons other than their diagnosis. Peter Pronovost, MD, PhD, FCCM, Chief Quality and Transformation Officer at University Hospitals Cleveland Medical Center, Cleveland, OH, discusses his work with the Parkinson’s Foundation developing new hospital care standards for reducing medication mismanagement and improper or insufficient care.

  • Dec 19, 2024 · 28 min

    Vagus Nerve Stimulation: Effects Beyond the Nervous System

    Stavros Zanos, MD, PhD, Associate Professor, Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, uses neurostimulation as a means to study the nervous system and to treat diseases in which the nervous system is affected or implicated. In this episode, Dr. Zanos gives an overview of the current understanding of Vagus Nerve Stimulation and shares important updates for future research and treatments beyond the nervous system.

  • Jan 19, 2024 · 10 min

    Discussing Disparities in MS Care for Underrepresented Populations

    In this episode, Trisham Gyang, MD, Clinical Assistant Professor of Neurology, The Ohio State University Wexner Medical Center, and Gopika Govindan Kutty, MD, Fellow, Department of Neurology, The Ohio State University Wexner Medical Center, provide strategies to assess biologic, genetic, and social factors in patients living with MS to help shrink the gap in care for underrepresented populations.

Showing 1–16 of 16 episodes